603858 步长制药
午间休市 01-08 11:29:54
资讯
新帖
简况
步长制药陷存货危机：45亿库存压仓，5.5亿纠纷未解，销售费高企研发乏力
蓝鲸财经 · 01-07 17:19
步长制药陷存货危机：45亿库存压仓，5.5亿纠纷未解，销售费高企研发乏力
流感疫情持续，防控系统工程再受考验
证券之星 · 2025-12-31
流感疫情持续，防控系统工程再受考验
步长制药子公司起诉捷迈上海，涉库存纠纷金额超6.5亿元
中金财经 · 2025-12-30
步长制药子公司起诉捷迈上海，涉库存纠纷金额超6.5亿元
步长制药最新公告：控股子公司泸州步长与MEDISPEC签署《独家供应协议》
证券之星 · 2025-12-29
步长制药最新公告：控股子公司泸州步长与MEDISPEC签署《独家供应协议》
每周股票复盘：步长制药（603858）拟出资180万设互联网子公司
证券之星 · 2025-12-28
每周股票复盘：步长制药（603858）拟出资180万设互联网子公司
步长制药最新公告：控股子公司拟180万元对外投资设立子公司
证券之星 · 2025-12-24
步长制药最新公告：控股子公司拟180万元对外投资设立子公司
步长制药最新公告：全资子公司拟750万元受让6个保健食品技术
证券之星 · 2025-12-24
步长制药最新公告：全资子公司拟750万元受让6个保健食品技术
步长制药（603858）披露全资子公司撤回药品上市许可注册申请，12月17日股价下跌0.06%
证券之星 · 2025-12-17
步长制药（603858）披露全资子公司撤回药品上市许可注册申请，12月17日股价下跌0.06%
步长制药最新公告：全资子公司撤回恩格列净片药品上市许可注册申请
证券之星 · 2025-12-17
步长制药最新公告：全资子公司撤回恩格列净片药品上市许可注册申请
步长制药获准变更药品生产许可证 受托生产范围扩大
中金财经 · 2025-12-16
步长制药获准变更药品生产许可证 受托生产范围扩大
步长制药下调对子公司泸州步长担保额度至2.05亿元
中金财经 · 2025-12-12
步长制药下调对子公司泸州步长担保额度至2.05亿元
步长制药（603858）披露控股子公司拟对外投资设立子公司，12月10日股价下跌0.24%
证券之星 · 2025-12-10
步长制药（603858）披露控股子公司拟对外投资设立子公司，12月10日股价下跌0.24%
步长制药：为公司控股子公司博源润步提供2200万元连带责任保证
证券日报 · 2025-12-07
步长制药：为公司控股子公司博源润步提供2200万元连带责任保证
步长制药为控股子公司博源润步提供2,200万元担保
中金财经 · 2025-12-06
步长制药为控股子公司博源润步提供2,200万元担保
步长制药（603858）披露全资子公司药品生产许可证变更，12月02日股价下跌1.17%
证券之星 · 2025-12-02
步长制药（603858）披露全资子公司药品生产许可证变更，12月02日股价下跌1.17%
步长制药最新公告：全资子公司签订参附益心颗粒注册临床试验委托合同
证券之星 · 2025-11-27
步长制药最新公告：全资子公司签订参附益心颗粒注册临床试验委托合同
步长制药（603858）披露公司签订药品注册临床试验委托合同的进展公告，11月26日股价上涨0.41%
证券之星 · 2025-11-26
步长制药（603858）披露公司签订药品注册临床试验委托合同的进展公告，11月26日股价上涨0.41%
每周股票复盘：步长制药（603858）取消监事会并补选董事
证券之星 · 2025-11-23
每周股票复盘：步长制药（603858）取消监事会并补选董事
步长制药（603858）披露拟购买安宫牛黄丸药品生产技术相关事宜进展公告，11月21日股价下跌3.52%
证券之星 · 2025-11-21
步长制药（603858）披露拟购买安宫牛黄丸药品生产技术相关事宜进展公告，11月21日股价下跌3.52%
步长制药（603858）披露控股子公司完成工商变更登记，11月19日股价下跌1.41%
证券之星 · 2025-11-19
步长制药（603858）披露控股子公司完成工商变更登记，11月19日股价下跌1.41%
加载更多
公司概况
公司名称：
山东步长制药股份有限公司
所属行业：
医药制造业
上市日期：
2016-11-18
主营业务：
山东步长制药股份有限公司的主营业务是中成药的研发、生产和销售。公司的主要产品是脑心通胶囊、稳心颗粒、丹红注射液、康妇炎胶囊、红核妇洁洗液、前列舒通胶囊、宣肺败毒颗粒、复方脑肽节苷脂注射液、复方曲肽注射液、谷红注射液、银杏蜜环口服溶液、流感病毒裂解疫苗、A群C群脑膜炎球菌多糖疫苗、ACYW135群脑膜炎球菌多糖疫苗。公司名列“2023年度中国中药企业TOP100排行榜”第四位。
发行价格：
55.88
{"stockData":{"symbol":"603858","market":"SH","secType":"STK","nameCN":"步长制药","latestPrice":16.43,"timestamp":1767842994000,"preClose":16.3,"halted":0,"volume":2751552,"delay":0,"changeRate":0.008,"floatShares":1055000000,"shares":1055000000,"eps":0.0016,"marketStatus":"午间休市","change":0.13,"latestTime":"01-08 11:29:54","open":16.29,"high":16.46,"low":16.25,"amount":45135700,"amplitude":0.0129,"askPrice":16.44,"askSize":5,"bidPrice":16.43,"bidSize":103,"shortable":0,"etf":0,"ttmEps":0.0016,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1767848400000},"marketStatusCode":3,"adr":0,"adjPreClose":16.3,"symbolType":"stock","openAndCloseTimeList":[[1767835800000,1767843000000],[1767848400000,1767855600000]],"highLimit":17.93,"lowLimit":14.67,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1054568442,"isCdr":false,"pbRate":1.63,"roa":"--","peRate":10268.75,"roe":"8.23%","epsLYR":-0.511,"committee":-0.249406,"marketValue":17327000000,"turnoverRate":0.0026,"status":0,"floatMarketCap":17327000000},"requestUrl":"/m/hq/s/603858","defaultTab":"news","newsList":[{"id":"2601875078","title":"步长制药陷存货危机：45亿库存压仓，5.5亿纠纷未解，销售费高企研发乏力","url":"https://stock-news.laohu8.com/highlight/detail?id=2601875078","media":"蓝鲸财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601875078?lang=zh_cn&edition=full","pubTime":"2026-01-07 17:19","pubTimestamp":1767777595,"startTime":"0","endTime":"0","summary":"此次案件涉案金额高达6.5189亿元人民币，其中库存价值约5.5亿元，利息及资金成本损失约9172.5万元。步长制药已在公告中进行了明确的风险提示，此次涉诉的5.5亿元左右存货存在计提存货跌价准备的风险。而值得注意的是，此次涉及诉讼只是步长制药整体存货的冰山一角，截至2025年三季度末，该公司存货已达45.17亿元，涉诉库存仅占总量的12%左右。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1767777433495411407","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BK0196","BK0239","603858"],"gpt_icon":0},{"id":"2595127727","title":"流感疫情持续，防控系统工程再受考验","url":"https://stock-news.laohu8.com/highlight/detail?id=2595127727","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595127727?lang=zh_cn&edition=full","pubTime":"2025-12-31 17:18","pubTimestamp":1767172695,"startTime":"0","endTime":"0","summary":"2025年末，全国流感疫情持续处于高流行水平。产业链协同响应，构建多层次供应保障流感防控是一项系统工程，需要疫苗预防、快速诊断、药物治疗等多个环节的有效衔接。本轮疫情中，上市药企正通过全产业链布局，搭建从源头预防到终端治疗的健康保障网络。中成药在本轮疫情中表现活跃。公司表示，金振口服液四季度市场需求回暖，正加紧排产满足市场需要。随着该产品儿童流感新适应症的获批，其在儿科领域的应用场景进一步拓宽。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/SS2025123100030908.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","BK0284","BK0175","BK0239","000756","300244","301207","BK0185","BK0010","BK0074","688276","BK0250","600557","002603","SG9999001069.SGD","BK0236","603858","BK0146","002317","BK0012","002393","BK0097","000999","BK0086","BK0197","600079","600566","BK0201","BK0183","000623","BK0042","BK0070","002728","BK0096","BK0077","BK0164","BK0046","BK0028","BK0114","603882","BK0187","BK0188","300937","BK0186","BK0060"],"gpt_icon":0},{"id":"2595876825","title":"步长制药子公司起诉捷迈上海，涉库存纠纷金额超6.5亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2595876825","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595876825?lang=zh_cn&edition=full","pubTime":"2025-12-30 11:19","pubTimestamp":1767064752,"startTime":"0","endTime":"0","summary":"核心事件源于双方经销协议期满后，上海合璞持有的约5.5亿元捷迈供应产品库存未能按行业惯例顺利转移至新任授权经销商。上海合璞的诉讼请求包括：要求被告按约5.56亿元净价回购剩余库存、退还预付款约320万元，并支付利息损失等，合计金额暂计约6.52亿元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20251230/31902756.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0239","BK0196","603858"],"gpt_icon":0},{"id":"2595784366","title":"步长制药最新公告：控股子公司泸州步长与MEDISPEC签署《独家供应协议》","url":"https://stock-news.laohu8.com/highlight/detail?id=2595784366","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595784366?lang=zh_cn&edition=full","pubTime":"2025-12-29 18:50","pubTimestamp":1767005425,"startTime":"0","endTime":"0","summary":"步长制药(603858.SH)公告称，公司控股子公司泸州步长拟与马来西亚公司MEDISPEC签署《独家供应协议》，泸州步长授权MEDISPEC作为目标区域内独家代理商，在目标区域内完成注射用Efparepoetin alfa的注册、推广、分销及销售事宜。本次交易不构成关联交易，也不构成重大资产重组。本事项无需提交公司股东会审议批准。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122900026897.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603858","BK0239","BK0196"],"gpt_icon":0},{"id":"2594423582","title":"每周股票复盘：步长制药（603858）拟出资180万设互联网子公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2594423582","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594423582?lang=zh_cn&edition=full","pubTime":"2025-12-28 03:38","pubTimestamp":1766864292,"startTime":"0","endTime":"0","summary":"截至2025年12月26日收盘，步长制药报收于16.45元，较上周的16.36元上涨0.55%。山东步长制药股份有限公司控股子公司步长众鑫康医药拟出资180万元，与湖北合俊腾辉贸易有限公司共同设立步长互联网（湖北）有限公司，注册资本300万元，持股比例60%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122800000816.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","159792","160636","603858","BK0239"],"gpt_icon":0},{"id":"2593147919","title":"步长制药最新公告：控股子公司拟180万元对外投资设立子公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2593147919","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593147919?lang=zh_cn&edition=full","pubTime":"2025-12-24 19:00","pubTimestamp":1766574046,"startTime":"0","endTime":"0","summary":"步长制药(603858.SH)公告称，公司控股子公司步长众鑫康医药拟出资180万元，与湖北合俊腾辉贸易有限公司共同投资设立步长互联网（湖北）有限公司，注册资本为300万元，步长众鑫康医药持股比例为60%。该投资事项无需提交股东会审议，不会对公司本年度财务状况和经营成果造成重大影响，但从长远来看，将对公司持续经营能力和企业综合竞争力产生积极影响。新公司可能面临宏观政策调控、市场变化及经营管理等因素的影响，后续投资收益存在不确定性。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122400031587.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603858","BK0196","BK0239"],"gpt_icon":0},{"id":"2593116479","title":"步长制药最新公告：全资子公司拟750万元受让6个保健食品技术","url":"https://stock-news.laohu8.com/highlight/detail?id=2593116479","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593116479?lang=zh_cn&edition=full","pubTime":"2025-12-24 19:00","pubTimestamp":1766574026,"startTime":"0","endTime":"0","summary":"步长制药(603858.SH)公告称，公司全资子公司山东丹红拟与陕西功能食品工程中心签署《技术转让合同》，以750万元人民币的价格受让云亭牌阿胶地黄口服液等6个保健食品的技术所有权。此次交易不构成关联交易，也不构成重大资产重组，已通过公司第五届董事会第三十九次会议审议。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122400031585.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603858","BK0196","BK0239"],"gpt_icon":0},{"id":"2592915904","title":"步长制药（603858）披露全资子公司撤回药品上市许可注册申请，12月17日股价下跌0.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2592915904","media":"证券之星","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592915904?lang=zh_cn&edition=full","pubTime":"2025-12-17 22:22","pubTimestamp":1765981358,"startTime":"0","endTime":"0","summary":"截至2025年12月17日收盘，步长制药报收于16.24元，较前一交易日下跌0.06%，最新总市值为171.26亿元。近日，山东步长制药股份有限公司发布公告称，其全资子公司山东丹红制药有限公司收到国家药品监督管理局签发的《药品注册申请终止通知书》，因恩格列净片需进一步完善申报资料，公司主动申请撤回该药品上市许可注册申请。恩格列净片适用于治疗2型糖尿病，截至公告日，该项目累计研发投入约1,500.68万元。公司后续将完善研究并择期重新提交注册申请。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121700039718.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603858","BK0196","BK0239"],"gpt_icon":0},{"id":"2592588996","title":"步长制药最新公告：全资子公司撤回恩格列净片药品上市许可注册申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2592588996","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592588996?lang=zh_cn&edition=full","pubTime":"2025-12-17 18:01","pubTimestamp":1765965690,"startTime":"0","endTime":"0","summary":"步长制药公告称，公司全资子公司山东丹红制药有限公司收到国家药品监督管理局签发的关于“恩格列净片”的《药品注册申请终止通知书》，同意药品注册申请撤回，终止注册程序。恩格列净片适用于治疗2型糖尿病，2022年至2024年在中国市场的销售额逐年增长。撤回申请是因为需要进一步完善申报资料，待完善后将择期重新提交申请。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121700028725.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","BK0239","603858"],"gpt_icon":0},{"id":"2591980990","title":"步长制药获准变更药品生产许可证 受托生产范围扩大","url":"https://stock-news.laohu8.com/highlight/detail?id=2591980990","media":"中金财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591980990?lang=zh_cn&edition=full","pubTime":"2025-12-16 21:52","pubTimestamp":1765893150,"startTime":"0","endTime":"0","summary":"中访网数据 山东步长制药股份有限公司近日公告，公司已获得山东省药品监督管理局批准，对《药品生产许可证》的委托和受托生产情况进行变更。公司表示，此次生产许可的变更有助于优化生产结构，维持稳定的生产能力，以满足市场需求，预计将对公司未来经营产生积极影响。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20251216/31870046.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0196","603858","BK0239"],"gpt_icon":0},{"id":"2590152025","title":"步长制药下调对子公司泸州步长担保额度至2.05亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2590152025","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590152025?lang=zh_cn&edition=full","pubTime":"2025-12-12 14:08","pubTimestamp":1765519696,"startTime":"0","endTime":"0","summary":"中访网数据 山东步长制药股份有限公司发布公告，披露了其为控股子公司提供担保的进展。公司此前于2021年与中信银行成都分行签订协议，为子公司四川泸州步长生物制药有限公司提供最高额3.5亿元的连带责任担保。近日，根据泸州步长的实际经营状况，双方协商签订了补充协议，将担保的最高债权额度调整为人民币2.05亿元。该担保范围覆盖债务本金及相应的利息、罚息、实现债权的费用等。协议其他条款及有效期保持不变。截至公告日，步长制药及控股子公司对外担保总额约为21.73亿元，占公司2024年末经审计净资产的21.27%，目前无逾期担保。此次调整反映了公司基于子公司经营现状对财务风险管理的动态把控。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20251212/31861959.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0196","BK0239","603858"],"gpt_icon":0},{"id":"2590538206","title":"步长制药（603858）披露控股子公司拟对外投资设立子公司，12月10日股价下跌0.24%","url":"https://stock-news.laohu8.com/highlight/detail?id=2590538206","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590538206?lang=zh_cn&edition=full","pubTime":"2025-12-10 22:14","pubTimestamp":1765376093,"startTime":"0","endTime":"0","summary":"截至2025年12月10日收盘，步长制药报收于16.54元，较前一交易日下跌0.24%，最新总市值为174.43亿元。该股当日开盘16.53元，最高16.62元，最低16.43元，成交额达7040.19万元，换手率为0.4%。公司近日发布公告称，其控股子公司步长金钥匙拟出资51万元，与尹卫群共同设立珠海大阡陌步长医药科技有限公司，注册资本100万元，步长金钥匙持股51%。董事会已审议通过该事项，无需提交股东会审议。新公司设立后可能存在政策、市场及经营管理等风险。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121000041532.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603858","BK0196"],"gpt_icon":0},{"id":"2589870678","title":"步长制药：为公司控股子公司博源润步提供2200万元连带责任保证","url":"https://stock-news.laohu8.com/highlight/detail?id=2589870678","media":"证券日报 ","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589870678?lang=zh_cn&edition=full","pubTime":"2025-12-07 20:36","pubTimestamp":1765110960,"startTime":"0","endTime":"0","summary":"证券日报网讯 12月5日晚间，步长制药发布公告称，公司于2025年12月4日与杭州银行北京自贸试验区支行签订《杭州银行股份有限公司最高额保证合同》，为公司控股子公司博源润步与杭州银行北京自贸试验区支行2025年11月6日至2027年5月5日签订的银行融资合同提供2，200万元连带责任保证。（文章来源：证券日报）\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2025-12-07/doc-infzyxcw4280175.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-12-07/doc-infzyxcw4280175.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["603858","BK0196","BK0239"],"gpt_icon":0},{"id":"2589825864","title":"步长制药为控股子公司博源润步提供2,200万元担保","url":"https://stock-news.laohu8.com/highlight/detail?id=2589825864","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589825864?lang=zh_cn&edition=full","pubTime":"2025-12-06 20:07","pubTimestamp":1765022823,"startTime":"0","endTime":"0","summary":"本次担保事项在公司2024年年度股东会审议通过的2025年度预计新增担保额度范围内，属于对资产负债率超过70%的控股子公司提供的担保。根据公告，博源润步为公司全资孙公司，截至2025年9月30日，其资产负债率为91.09%。截至公告日，公司及控股子公司对外担保总额为231,830.79万元，占公司2024年末经审计净资产的22.69%，目前无逾期担保。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20251206/31848992.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0239","603858","BK0196"],"gpt_icon":0},{"id":"2588603946","title":"步长制药（603858）披露全资子公司药品生产许可证变更，12月02日股价下跌1.17%","url":"https://stock-news.laohu8.com/highlight/detail?id=2588603946","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588603946?lang=zh_cn&edition=full","pubTime":"2025-12-02 17:53","pubTimestamp":1764669201,"startTime":"0","endTime":"0","summary":"截至2025年12月2日收盘，步长制药报收于16.96元，较前一交易日下跌1.17%，最新总市值为178.85亿元。公司于近日发布公告称，其全资子公司保定天浩制药有限公司获得河北省药品监督管理局许可，同意其《药品生产许可证》的车间生产线及药品委托生产情况变更。保定天浩制药有限公司委托陕西步长制药有限公司生产两种规格的维生素D滴剂，委托有效期至2030年7月7日，仅限注册申报使用。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120200027047.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603858","BK0196"],"gpt_icon":0},{"id":"2586241715","title":"步长制药最新公告：全资子公司签订参附益心颗粒注册临床试验委托合同","url":"https://stock-news.laohu8.com/highlight/detail?id=2586241715","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586241715?lang=zh_cn&edition=full","pubTime":"2025-11-27 18:40","pubTimestamp":1764240014,"startTime":"0","endTime":"0","summary":"步长制药(603858.SH)公告称，公司全资子公司山东丹红制药与北京卓越未来国际医药科技发展有限公司签订《参附益心颗粒注册临床试验委托合同》，委托北京卓越完成参附益心颗粒注册临床试验。合同涉及费用总价6033.8万元（含税），若最终样本量超过520例，超过部分按照单例含税费用108890元计算。该事项有利于扩大公司药品研发能力和范围，节约药品临床试验的时间和成本，不会对公司财务状况和经营成果产生不利影响。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112700028428.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603858","BK0239","BK0196"],"gpt_icon":0},{"id":"2586081230","title":"步长制药（603858）披露公司签订药品注册临床试验委托合同的进展公告，11月26日股价上涨0.41%","url":"https://stock-news.laohu8.com/highlight/detail?id=2586081230","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586081230?lang=zh_cn&edition=full","pubTime":"2025-11-26 17:48","pubTimestamp":1764150513,"startTime":"0","endTime":"0","summary":"截至2025年11月26日收盘，步长制药报收于17.13元，较前一交易日上涨0.41%，最新总市值为180.65亿元。该股当日开盘17.08元，最高17.59元，最低17.08元，成交额达1.19亿元，换手率为0.65%。同日，步长制药发布公告披露关于公司签订药品注册临床试验委托合同的进展。北京卓越需配合资料移交并协助签署新的临床试验委托合同。原合同首期款1,660.14万元由北京卓越退还。补充协议与原合同不一致的，以补充协议为准。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112600026987.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603858","BK0239","BK0196"],"gpt_icon":0},{"id":"2585010322","title":"每周股票复盘：步长制药（603858）取消监事会并补选董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2585010322","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585010322?lang=zh_cn&edition=full","pubTime":"2025-11-23 02:59","pubTimestamp":1763837948,"startTime":"0","endTime":"0","summary":"截至2025年11月21日收盘，步长制药报收于16.74元，较上周的18.32元下跌8.62%。本周关注点公司公告汇总：步长制药召开2025年第一次临时股东会，审议通过取消监事会、调整董事会人数等议案。公司公告汇总：步长制药为两家控股子公司提供合计15,600万元连带责任保证担保。公司于2025年11月17日召开职工代表大会，选举吴兵先生为第五届董事会职工代表董事，任期至本届董事会任期届满。此前公司已于2025年3月完成该品种上市许可持有人变更至步长制药。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112300000709.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603858","BK0239","BK0196"],"gpt_icon":0},{"id":"2585912149","title":"步长制药（603858）披露拟购买安宫牛黄丸药品生产技术相关事宜进展公告，11月21日股价下跌3.52%","url":"https://stock-news.laohu8.com/highlight/detail?id=2585912149","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585912149?lang=zh_cn&edition=full","pubTime":"2025-11-21 22:30","pubTimestamp":1763735411,"startTime":"0","endTime":"0","summary":"截至2025年11月21日收盘，步长制药报收于16.74元，较前一交易日下跌3.52%，最新总市值为176.53亿元。该股当日开盘17.3元，最高17.45元，最低16.71元，成交额达1.48亿元，换手率为0.83%。公司近日发布公告称，山东步长制药股份有限公司于2025年3月完成安宫牛黄丸上市许可持有人变更，由辽宁汉草堂变更为步长制药。该事项有利于丰富公司产品线，提升市场竞争力，但未来销售受政策及市场环境影响存在不确定性。公司在该项目上累计投入研发费用约1,196.55万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112100040263.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0196","603858"],"gpt_icon":0},{"id":"2584594784","title":"步长制药（603858）披露控股子公司完成工商变更登记，11月19日股价下跌1.41%","url":"https://stock-news.laohu8.com/highlight/detail?id=2584594784","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584594784?lang=zh_cn&edition=full","pubTime":"2025-11-19 22:20","pubTimestamp":1763562041,"startTime":"0","endTime":"0","summary":"截至2025年11月19日收盘，步长制药报收于17.47元，较前一交易日下跌1.41%，最新总市值为184.23亿元。该股当日开盘17.68元，最高17.77元，最低17.4元，成交额达8762.18万元，换手率为0.47%。近日，山东步长制药股份有限公司发布公告称，其控股子公司济南步长财淦商贸有限公司已完成工商变更登记，并取得莱芜高新技术产业开发区市场监督管理局换发的营业执照。本次变更为住所变更，变更后住所为山东省济南市莱芜高新区鹏泉街道世纪城路1号世纪城46幢南B1单元1710。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111900039944.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0196","603858"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1767847842188,"stockEarnings":[{"period":"1week","weight":0.0422},{"period":"1month","weight":-0.0338},{"period":"3month","weight":-0.1073},{"period":"6month","weight":-0.0137},{"period":"1year","weight":0.0734},{"period":"ytd","weight":0.0422}],"compareEarnings":[{"period":"1week","weight":0.0295},{"period":"1month","weight":0.0412},{"period":"3month","weight":0.0386},{"period":"6month","weight":0.164},{"period":"1year","weight":0.2651},{"period":"ytd","weight":0.0295}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"山东步长制药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"51090人(较上一季度减少7.36%)","perCapita":"20641股","listingDate":"2016-11-18","address":"山东省菏泽市牡丹区中华西路369号","registeredCapital":"105456万元","survey":" 山东步长制药股份有限公司的主营业务是中成药的研发、生产和销售。公司的主要产品是脑心通胶囊、稳心颗粒、丹红注射液、康妇炎胶囊、红核妇洁洗液、前列舒通胶囊、宣肺败毒颗粒、复方脑肽节苷脂注射液、复方曲肽注射液、谷红注射液、银杏蜜环口服溶液、流感病毒裂解疫苗、A群C群脑膜炎球菌多糖疫苗、ACYW135群脑膜炎球菌多糖疫苗。公司名列“2023年度中国中药企业TOP100排行榜”第四位。","listedPrice":55.88},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"步长制药(603858)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供步长制药(603858)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"步长制药,603858,步长制药股票,步长制药股票老虎,步长制药股票老虎国际,步长制药行情,步长制药股票行情,步长制药股价,步长制药股市,步长制药股票价格,步长制药股票交易,步长制药股票购买,步长制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"步长制药(603858)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供步长制药(603858)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}